Skip to content

Effect of Ayurveda treatment in the Management of Tamaka Shwasa(Bronchial Asthma)

Clinical trial to study the Effect of Vyoshadi Granules, Vasadi Kashaya & Erand Bhrishta Haritaki in Tamaka Shwasa (Bronchial Asthma) - Ayurveda treatment in Bronchial Asthma

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/07/044267
Enrollment
30
Registered
2022-07-22
Start date
Unknown
Completion date
Unknown
Last updated
2022-08-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J454- Moderate persistent asthma

Interventions

None listed

Sponsors

National Institute of Ayurveda
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: • Patients willing to participate and sign consent in the clinical trial. • Patients in the age group of 18-65 yrs. • Patients with Intermittent, mild-persistent & moderate-persistent asthma and are not on regular medication for Asthma. • Patients having FEV1 > 60% of predicted value • Patients of Rhinitis with spirometric evidence of reversible airflow obstruction. • Patients who have not received any AYUSH intervention in last 15 days for related symptoms

Exclusion criteria

Exclusion criteria: • Patients having severe persistent (FEV1 • Diagnosed cases of tuberculosis, pneumonia, COPD and other acute and chronic pulmonary disorders • K/c/o malignancies of the respiratory and other system. • Patients who have consumed AYUSH intervention for related complaints in last 15 days. • Patients on regular anti allergic medications, on regular inhaled, intranasal or oral steroids. • Patients on immunotherapy for allergy. • Patients with Haemoglobin less than 9 mg/dl. • Patients having concomitant systemic illness like uncontrolled Hypertension, Poorly controlled Diabetes Mellitus, Renal failure, Malignancy, Acute or Chronic liver disease.

Design outcomes

Primary

MeasureTime frame
â?¢ Forced Expiratory Volume in first second (FEV1) from baseline values.Timepoint: 56 days

Secondary

MeasureTime frame
â?¢ Improvement in Peak expiratory flow rate (PEFR). â?¢ Changes in IgE & Absolute Eosinophil count â?¢ Degree of improvement in asthma related symptoms on the basis of Asthma control questionnaire (ACQ) â?¢ Degree of Improvement in Total Nasal Symptom Score (TNSS) Timepoint: 56 days

Countries

India

Contacts

Public ContactDr Abhishek Upadhyay

National Institute of Ayurveda

dr.abhishek82@gmail.com9915613039

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026